1. Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive Drugs.
- Author
-
Garritsen FM, van der Schaft J, van den Reek JM, Politiek K, van Os-Medendorp H, van Dijk M, Hijnen DJ, de Graaf M, Bruijnzeel-Koomen CA, de Jong EM, Schuttelaar MA, and Bruin-Weller MS
- Subjects
- Academic Medical Centers, Administration, Oral, Adult, Aged, Carcinoma, Basal Cell chemically induced, Carcinoma, Basal Cell immunology, Carcinoma, Basal Cell pathology, Carcinoma, Squamous Cell chemically induced, Carcinoma, Squamous Cell immunology, Carcinoma, Squamous Cell pathology, Dermatitis, Atopic diagnosis, Dermatitis, Atopic immunology, Drug Therapy, Combination, Female, Humans, Immunocompromised Host, Immunosuppressive Agents adverse effects, Incidence, Male, Middle Aged, Netherlands epidemiology, Retrospective Studies, Risk Assessment, Risk Factors, Skin Neoplasms chemically induced, Skin Neoplasms immunology, Skin Neoplasms pathology, Time Factors, Treatment Outcome, Carcinoma, Basal Cell epidemiology, Carcinoma, Squamous Cell epidemiology, Dermatitis, Atopic drug therapy, Immunosuppressive Agents administration & dosage, Skin Neoplasms epidemiology
- Abstract
There is uncertainty about the risk of developing non-melanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in patients with atopic dermatitis (AD) treated with oral immunosuppressive drugs. A total of 557 patients with AD treated with these drugs in the University Medical Center Utrecht and Groningen, the Netherlands, were analysed. NMSC after oral immunosuppressive treatment was reported in 18 patients (3.2%). The standardized incidence ratio for developing SCC was 13.1 (95% confidence interval (95% CI) 6.5-19.7). Patients developing NMSC were older at the start of therapy (p<0.001) and data lock (p<0.001) compared with patients without NMSC. No significant differences were found in sex, cumulative days of oral immunosuppressive drugs and follow-up between these groups (p=0.42, p=0.88, and p=0.34, respectively). In interpreting these results it is important to include other factors, such as lack of association between treatment duration and tumour development and the long interval between treatment discontinuation and tumour development in some patients.
- Published
- 2017
- Full Text
- View/download PDF